Pasar al contenido principal

DESCIFRANDO EL POTENCIAL TERAPEUTICO DEL RECEPTOR HUERFANO GPR12 EN LA ENFERMEDAD DE PARKINSON

PID2022-139197OA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Progress on the development of Class A GPCR-biased ligands

  • Morales, Paula
  • Scharf, Magdalena M.
  • Bermudez, Marcel
  • Egyed, Attila
  • Franco, Rafael
  • Hansen, Olivia K.
  • Jagerovic, Nadine
  • Jakubík, Jan
  • Keserű, György M.
  • Kiss, Dóra Judit
  • Kozielewicz, Pawel
  • Larsen, Olav
  • Majellaro, Maria
  • Mallo-Abreu, Ana
  • Navarro, Gemma
  • Prieto-Díaz, Rubén
  • Rosenkilde, Mette M.
  • Sotelo, Eddy
  • Stark, Holger
  • Werner, Tobias
  • Wingler, Laura M.
Class A G protein-coupled receptors (GPCRs) continue to garner interest for their essential roles in cell signalling and their importance as drug targets. Although numer- ous drugs in the clinic target these receptors, over 60% GPCRs remain unexploited. Moreover, the adverse effects triggered by the available unbiased GPCR modulators, limit their use and therapeutic value. In this context, the elucidation of biased signal- ling has opened up new pharmacological avenues holding promise for safer therapeu- tics. Functionally selective ligands favour receptor conformations facilitating the recruitment of specific effectors and the modulation of the associated pathways. This review surveys the current drug discovery landscape of GPCR-biased modulators with a focus on recent advances. Understanding the biological effects of this prefer- ential coupling is at different stages depending on the Class A GPCR family. There- fore, with a focus on individual GPCR families, we present a compilation of the functionally selective modulators reported over the past few years. In doing so, we dissect their therapeutic relevance, molecular determinants and potential clinical applications., National Office of Research, Development and Innovation, Grant/Award Number: RRF- 2.3.1-21-2022-00015; Ministerio de Ciencia e Innovación, Grant/Award Numbers: FJC2021-047571-I, PID2020-118511RB-I00, PID2021-124010OB-100, PID2021-126600OB-I00, PID2021-127833OB-I00, PID2022- 139197OA-I00; Cancerfonden, Grant/Award Number: 20 0264; National Institutes of Health, Grant/Award Number: R01 DA0455698; German Research Foundation, Grant/Award Numbers: 470002134, GRK 2158; Swedish Society for Medical Research, Grant/Award Number: PG-22-0379-H-01; Hungarian Academy of Sciences, Grant/Award Number: NAP 3.0; Consellería de Cultura, Educación e Ordenación Universitaria of the Galician Government, Grant/Award Number: ED431B 2020/43; Centro Singular de Investigación de Galicia Accreditation 2019– 2022, Grant/Award Number: ED431G 2019/03; MCIN/ AEI/10.13039/501100011033/FEDER, UE, Grant/Award Number: FJC2021-047571-I; Karolinska Institutet, the Swedish Cancer Society, Grant/Award Number: 20 0264; Swedish Research Council, Grant/Award Number: 2022-01398; Czech Academy of Sciences, Grant/Award Number: 67985823; Grant Agency of Czech Republic, Grant/Award Number: 23-04670S; Juan de la Cierva Incorporación Programme, Grant/Award Number: IJC 2019-042182-I; The Pew Charitable Trusts; COST (European Cooperation in Science and Technology), Grant/Award Number: CA18133, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Homodimerization of CB2 cannabinoid receptor triggered by a bivalent ligand enhances cellular signaling

  • Navarro, Gemma
  • Gómez-Autet, Marc
  • Morales, Paula
  • Biel Rebassa, Joan
  • Llinas del Torrent, Claudia
  • Jagerovic, Nadine
  • Pardo, Leonardo
  • Franco, Rafael
G protein-coupled receptors (GPCRs) exist within a landscape of interconvertible conformational states and in dynamic equilibrium between monomers and higher-order oligomers, both influenced by ligand binding. Here, we show that a homobivalent ligand formed by equal chromenopyrazole moieties as pharmacophores, connected by 14 methylene units, can modulate the dynamics of the cannabinoid CB2 receptor (CB2R) homodimerization by simultaneously binding both protomers of the CB2R-CB2R homodimer. Computational and pharmacological experiments showed that one of the ligand pharmacophores binds to the orthosteric site of one protomer, and the other pharmacophore to a membrane-oriented pocket between transmembranes 1 and 7 of the partner protomer. This results in unique pharmacological properties, including increased potency in Gi-mediated signaling and enhanced recruitment of β-arrestin. Thus, by modulating dimerization dynamics, it may be possible to fine-tune CB2R activity, potentially leading to improved therapeutic outcomes, We acknowledge the financial support from the Spanish Ministry of Science and Innovation with FEDER funds (PID2020-113430RB-I00, PID2021-126600OB-I00, PDC2022-133171-I00, PID2022-140912OB- I00, PID2021-127833OB-I00, PID2022-139197OA-I00) and Generalitat de Catalunya (2021 SGR 00304). C.L.T. is recipient of a FPI fellowship (BES-2017-081872) and M.G.-A. acknowledges the Universitat Autonoma de Barcelona for his predoctoral grant., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting APC/C Ubiquitin E3-Ligase Activation with Pyrimidinethylcarbamate Apcin Analogues for the Treatment of Breast Cancer

  • Kapanidou, Maria
  • Curtis, Natalie L.
  • Díaz-Mínguez, Sandra S.
  • Agudo-Álvarez, Sandra
  • Rus Sanchez, Alfredo
  • Mayah, Ammar
  • Agena, Rosette
  • Brennan, Paul
  • Morales, Paula
  • Benito-Arenas, Raul
  • Bastida, Agatha
  • Bolanos-Garcia, Victor M.
Activation of the ubiquitin ligase APC/C by the protein Cdc20 is an essential requirement for proper cell division in higher organisms, including humans. APC/C is the ultimate effector of the Spindle Assembly Checkpoint (SAC), the signalling system that monitors the proper attachment of chromosomes to microtubules during cell division. Defects in this process result in genome instability and cancer. Interfering with APC/C substrate ubiquitylation in cancer cells delays mitotic exit, which induces cell death. Therefore, impairing APC/C function represents an opportunity for the treatment of cancer and malignancies associated with SAC dysregulation. In this study, we report a new class of pyrimidinethylcarbamate apcin analogues that interfere with APC/C activity in 2D and 3D breast cancer cells. The new pyrimidinethylcarbamate apcin analogues exhibited higher cytotoxicity than apcin in all breast cancer cell subtypes investigated, with much lower cytotoxicity observed in fibroblasts and RPE-1 cells. Further molecular rationalisation of apcin and its derivatives was conducted using molecular docking studies. These structural modifications selected from the in silico studies provide a rational basis for the development of more potent chemotypes to treat highly aggressive breast cancer and possibly other aggressive tumour types of diverse tissue origins., M.K. and N.C. were each supported by a Professor Nigel Groome PhD Studentship, Oxford Brookes University. Initial work was supported by Cancer Research UK (CRUK) grant number C5255/A18085 through the CRUK Oxford Centre to V.B.M.-G. and P.B. P.M. was supported by Ministerio de Ciencia, Innovación y Universidades grant PID2022-139197OA-I00/AEI/10.13039/501100011033/FEDER, UE. R.A. was supported by the Escuela Nacional de Ciencias Biológicas (ENCB), Instituto Politécnico Nacional. A.B. and V.B.M.-G. were supported by the Spanish Ministry of Science and Innovation, I-LINK programme (grant ref. LINKB20075). A.M., N.C. and V.B.M.-G. were supported by Innovate UK (ref. 10031340)., Peer reviewed